Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin (Q36428052)

14 August 2017

Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin (English)

1 reference

14 August 2017

1 reference

1 reference

Anja Schweizer

1

1 reference

PMCID

3508106

14 August 2017

Sylvie Dejager

series ordinal

2

1 reference

PMCID

3508106

14 August 2017

James E Foley

series ordinal

3

1 reference

14 August 2017

27 June 2012

1 reference

14 August 2017

1 reference

14 August 2017

3

1 reference

14 August 2017

1

1 reference

14 August 2017

8

1 reference

Creative Commons Attribution 2.0 Generic

14 August 2017

start time

27 June 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s13300-012-0008-5

0 references

cites work

Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Linagliptin: in type 2 diabetes mellitus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Vildagliptin: a review of its use in type 2 diabetes mellitus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

The role of GLP-1 in the life and death of pancreatic beta cells.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Gut hormones and diabetes mellitus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

The incretin concept today

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

28 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Comparison of pioglitazone and metformin efficacy using homeostasis model assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Predictors of response to glimepiride in patients with type 2 diabetes mellitus

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3508106

Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus

21 September 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-012-0008-5

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22736406

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22736406

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13300-012-0008-5

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

PMCID

3508106